Par Adds To HIV Portfolio With Immtech’s Pafuramidine
This article was originally published in The Pink Sheet Daily
Executive Summary
Par is projecting a late 2007 or early 2008 NDA submission for pneumocystis pneumonia in AIDS, the firm tells “The Pink Sheet” DAILY.